Despite reporting a Phase 3 win this summer, Pfizer terminated its hemophilia A gene therapy pact with Sangamo Therapeutics in…
Author: Kyle LaHucik
A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been…
BioNTech has entered into settlement agreements with the NIH and the University of Pennsylvania, marking a key turning point in…
Inmagene Biopharmaceuticals, a biotech developing immunology treatments, will take over the Nasdaq listing of Ikena Oncology in a reverse merger…
Rhythm Pharmaceuticals received FDA approval to market its genetic obesity drug Imcivree for children as young as 2 years old.…
Sofinnova Investments, one of the longest-standing biotech investment firms, has penciled in plans for a new $550 million fund, Endpoints…
Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company told Endpoints…
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2…
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier…
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it’s happening years after some…